Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) (AESOP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02177136|
Recruitment Status : Active, not recruiting
First Posted : June 27, 2014
Last Update Posted : January 24, 2018
|Condition or disease||Intervention/treatment||Phase|
|Primary Sclerosing Cholangitis (PSC)||Drug: OCA Drug: Placebo||Phase 2|
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-finding evaluation of the efficacy and safety of OCA in subjects with PSC. Approximately 75 subjects who provide written informed consent and meet all of the inclusion and none of the exclusion criteria will be randomized to 1 of 3 treatment groups as follows: 1.5 mg titrating to 3 mg OCA, 5 mg titrating to 10 mg OCA, or placebo, in a 1:1:1 ratio. Subjects will administer investigational product (IP) orally, once daily for 2 consecutive 12-week periods.
For the first 12 weeks, the subject's dose will be 1.5 mg OCA, 5 mg OCA, or placebo. After 12 weeks, the subject's dose will be titrated as follows, providing there are no limiting safety or tolerability concerns in the opinion of the investigator, while maintaining the trial blind: the 1.5 mg OCA treatment group will titrate to 3 mg, the 5 mg OCA treatment group will titrate to 10 mg OCA, and the placebo group will remain on placebo. Double-blind treatment will continue for a further 12 weeks at that dose.
Any subjects whose dose is not titrated, due to safety or tolerability concerns, will remain on their starting treatment (1.5 mg OCA, 5 mg OCA, or placebo) for the remainder of the double-blind phase to Week 24.
Randomization will be stratified by the presence or absence of concomitant ursodeoxycholic acid (UDCA) use and total bilirubin level (≤ 1.5x upper limit of normal [ULN] or > 1.5x ULN but < 2.5x ULN).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||77 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis|
|Study Start Date :||December 2014|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||June 2019|
Experimental: 1.5 mg OCA titrating to 3 mg OCA
Subjects randomized to 1.5 mg will take 1.5 mg OCA daily for 12 weeks followed by 3 mg OCA for an additional 12 weeks.
Experimental: 5 mg OCA titrating to 10 mg OCA
Subjects randomized to 5 mg will take 5 mg OCA daily for 12 weeks followed by 10 mg OCA for an additional 12 weeks.
Subjects randomized to placebo will take placebo for 24 weeks
- Evaluate the effects of obeticholic acid (OCA) on serum alkaline phosphatase (ALP) in subjects with Primary Sclerosing Cholangitis (PSC) [ Time Frame: 24 weeks ]
- Evaluate the effects of OCA on safety in subjects with PSC [ Time Frame: 24 weeks ]
- Hepatic biochemistry and indices of function [ Time Frame: 24 weeks ]
- Hepatic Fibrosis [ Time Frame: 24 weeks ]
- Gastrointestinal inflammation and disease [ Time Frame: 24 weeks ]
- Farnesoid X receptor (FXR) activity [ Time Frame: 24 weeks ]
- Inflammatory bowel disease (IBD) [ Time Frame: 24 weeks ]
- Exposure response of total OCA (OCA and its conjugates) to biomarkers [ Time Frame: 24 weeks ]
- Long-term efficacy [ Time Frame: 24 months ]
- Long term safety [ Time Frame: 24 months ]
- Disease-specific symptoms [ Time Frame: 24 weeks ]
- Pharmacokinetics (PK) of OCA and other bile acids [ Time Frame: 24 Weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02177136
Show 35 Study Locations
|Study Director:||David Shapiro, MD||Intercept Pharmaceuticals|